
Syntis Bio develops novel oral therapies with targeted drug delivery technology to enhance bioavailability.
Syntis Bio, founded with the mission to revolutionize drug delivery, focuses on developing novel oral therapies that utilize advanced targeted delivery technology to enhance bioavailability. The company's core vision is to improve patient outcomes by creating more effective and efficient drug formulations. Their primary market focus is on late-stage preclinical development, aiming to address unmet medical needs through innovative therapeutic solutions.
Notable figures associated with Syntis Bio include experienced scientists and industry veterans who bring a wealth of knowledge in pharmaceutical development. The company has garnered attention from prominent investors in the biotech sector, underscoring its potential impact. Key achievements include significant advancements in their drug delivery technology, positioning Syntis Bio as a promising player in the field of targeted oral therapies. Their work has the potential to transform treatment paradigms and improve the efficacy of various medications.

i2o Therapeutics
i2obio.com

Synereca Pharmaceuticals

Forward Therapeutics
forward-tx.com

Synnovation Therapeutics
synnovationtx.com

Concours Pharmaceuticals

Cytonus Therapeutics
cytonus.com

Synspira

Transpire Bio
transpirebio.com

Lindy Biosciences
lindybio.com

Receptor Life Sciences
receptorlife.com

SpringLeaf Therapeutics

Intact Therapeutics

Synthex

bioSyntagma
biosyntagma.com

Surf Bio
surf.bio
Companies similar to Syntis Bio include i2o Therapeutics, Synereca Pharmaceuticals, Forward Therapeutics and Synnovation Therapeutics.
Syntis Bio was founded in 2022.
Syntis Bio's headquarters is located in Milton, MA, US.
Syntis Bio's most recent funding round was for $15.4M (USD) in January 2023.
As of Jan 17, 2023, Syntis Bio has raised a total of $15.4M (USD).
Syntis Bio has 7 employees as of Feb 5, 2024.